ADMA BIOLOGICS, INC.

ADMAUnited States

88 filed reports · 663 financial concepts · 13 earnings calls

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

Latest fiscal year

Revenue

$510M

FY2025 · to Dec 31, 2025

up +19.6% vs $426M

10-K

Operating income

$191M

FY2025 · to Dec 31, 2025

up +37.7% vs $139M

10-K

Latest quarter

Revenue

$141M

Q3 FY2026 · to Sep 30, 2026

up +5.1% vs $134M

10-Q

Operating income

$67.8M

Q3 FY2026 · to Sep 30, 2026

up +32.8% vs $51M

10-Q

Filed reports

88 reports · Sep 2011 to Sep 2026

Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 75 guidance figures, 102 earnings-release figures, 55 commentary passages.

Report typeReportsFactsPeriods
Quarterly · 10-QSEC EDGAR477,965Sep 2011 to Sep 2026
Current · 8-KSEC EDGAR27179Dec 2020 to Sep 2026
Annual · 10-KSEC EDGAR145,699Dec 2012 to Dec 2025

Documents

PeriodTypePeriod endPublishedFactsSource
FY2026 Q310-Q2026-09-302026-11-04422Open
FY2026 Q38-K2026-09-302026-11-04104Open
FY2026 Q210-Q2026-06-302026-08-05273Open
FY2026 Q28-K2026-06-302026-08-052Open
FY2026 Q18-K2026-03-312026-05-062Open
FY2026 Q110-Q2026-03-312026-05-06273Open
FY202510-K2025-12-312026-02-25854Open
FY2025 Q48-K2025-12-312026-02-253Open
FY2025 Q48-K2025-12-312026-01-125Open
FY2025 Q310-Q2025-09-302025-11-05172Open
FY2025 Q38-K2025-09-302025-11-053Open
FY2025 Q210-Q2025-06-302025-08-06157Open

Financial data

663 concepts · 13,843 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial578 concepts · 11,011 facts · Jun 2006 to Sep 2026

  • Stockholders equity (US GAAP)88 · Jun 2006 to Sep 2026
  • Net income loss85 · Jun 2007 to Sep 2026
  • Cash and cash equivalents at carrying value83 · Jun 2010 to Sep 2026
  • Increase decrease in accrued liabilities80 · Sep 2010 to Sep 2026
  • Net cash provided by used in operating activities80 · Sep 2010 to Sep 2026
  • Operating expenses (US GAAP)80 · Sep 2010 to Sep 2026
  • Other cost and expense operating80 · Sep 2010 to Sep 2026
  • Additional paid in capital78 · Jun 2011 to Sep 2026
  • Assets78 · Jun 2011 to Sep 2026
  • Common stock par or stated value per share78 · Jun 2011 to Sep 2026
  • Common stock shares authorized78 · Jun 2011 to Sep 2026
  • Common stock shares issued78 · Jun 2011 to Sep 2026
  • Common stock shares outstanding78 · Jun 2011 to Sep 2026
  • Common stock value78 · Jun 2011 to Sep 2026
  • Depreciation and amortization78 · Mar 2011 to Sep 2026
  • Increase decrease in accounts payable78 · Mar 2011 to Sep 2026
  • Increase decrease in accounts receivable78 · Mar 2011 to Sep 2026
  • Increase decrease in inventories78 · Mar 2011 to Sep 2026
  • Liabilities and stockholders equity78 · Jun 2011 to Sep 2026
  • Liabilities current78 · Jun 2011 to Sep 2026
  • Net cash provided by used in financing activities78 · Mar 2011 to Sep 2026
  • Operating income loss78 · Mar 2011 to Sep 2026
  • Research and development expense78 · Mar 2011 to Sep 2026
  • Revenue78 · Mar 2011 to Sep 2026

Segment32 concepts · 2,497 facts · Mar 2011 to Sep 2026

  • Revenue344 · Dec 2011 to Sep 2026
  • Depreciation and amortization261 · Mar 2011 to Sep 2026
  • Operating income loss247 · Mar 2011 to Sep 2024
  • Nonoperating income expense173 · Mar 2011 to Sep 2026
  • Cost of revenue (US GAAP)155 · Mar 2017 to Sep 2026
  • Net income loss155 · Mar 2016 to Dec 2023
  • Income loss from continuing operations before income taxes extraordinary items noncontrolling interest139 · Mar 2011 to Sep 2026
  • Total Assets96 · Mar 2018 to Jun 2026
  • Cost of goods sold93 · Mar 2012 to Mar 2018
  • Gross profit (US GAAP)93 · Mar 2012 to Dec 2018
  • Property and equipment, net80 · Mar 2011 to Dec 2016
  • Operating Segments75 · Mar 2020 to Dec 2023
  • Payments to acquire property plant and equipment64 · Mar 2018 to Mar 2023
  • Other nonoperating income expense61 · Mar 2018 to Mar 2021
  • Total assets59 · Mar 2015 to Dec 2019
  • ADMA BioManufacturing57 · Mar 2019 to Mar 2021
  • Segment expenditure addition to long lived assets56 · Dec 2021 to Sep 2026
  • Gains losses on extinguishment of debt47 · Mar 2019 to Dec 2023
  • Capital expenditures36 · Sep 2016 to Dec 2019
  • Gain loss on sale of other assets30 · Mar 2019 to Sep 2020
  • General and administrative expense (US GAAP)30 · Dec 2022 to Sep 2026
  • Research and development expense30 · Dec 2022 to Sep 2026
  • Selling and marketing expense (US GAAP)30 · Dec 2022 to Sep 2026
  • Other cost and expense operating24 · Dec 2022 to Dec 2025

KPI46 concepts · 101 facts · Sep 2025 to Sep 2026

  • Non-recurring professional fees6 · Sep 2025 to Sep 2026
  • Amortization4 · Sep 2025 to Sep 2026
  • Depreciation4 · Sep 2025 to Sep 2026
  • EBITDA4 · Sep 2025 to Sep 2026
  • Income taxes4 · Sep 2025 to Sep 2026
  • Interest expense, net4 · Sep 2025 to Sep 2026
  • License revenue4 · Sep 2025 to Sep 2026
  • Prepaid expenses and other current assets4 · Sep 2025 to Sep 2026
  • Stock-based compensation4 · Sep 2025 to Sep 2026
  • Accounts payable2 · Sep 2025 to Sep 2026
  • Accounts receivable2 · Sep 2025 to Sep 2026
  • Accrued expenses2 · Sep 2025 to Sep 2026
  • Accrued expenses and other current liabilities2 · Dec 2025 to Sep 2026
  • Acquisition of intangible assets2 · Sep 2025 to Sep 2026
  • Acquisition of treasury stock2 · Sep 2025 to Sep 2026
  • Amortization of debt discount2 · Sep 2025 to Sep 2026
  • Amortization of license revenue2 · Sep 2025 to Sep 2026
  • Cash and cash equivalents - end of period2 · Sep 2025 to Sep 2026
  • Deferred income tax provision2 · Sep 2025 to Sep 2026
  • Deposits and other assets2 · Sep 2025 to Sep 2026
  • Depreciation and amortization2 · Sep 2025 to Sep 2026
  • Inventories2 · Sep 2025 to Sep 2026
  • JPM revolving facility proceeds2 · Sep 2025 to Sep 2026
  • JPM term loan payments2 · Sep 2025 to Sep 2026

Geography1 concept · 89 facts · Mar 2020 to Sep 2026

  • Revenue89 · Mar 2020 to Sep 2026

Guidance4 concepts · 77 facts · Jan 2021 to Nov 2026

  • Revenue Guidance62 · Jan 2021 to Nov 2026
  • Net Income Guidance12 · Jan 2024 to Jan 2025
  • Revenue Growth Guidance2 · Jan 2023
  • Net Income Guidance (Adjusted (non-GAAP))1 · Nov 2026

Product2 concepts · 68 facts · Mar 2020 to Dec 2025

  • Research and development expense38 · Sep 2021 to Dec 2025
  • Revenue30 · Mar 2020 to Dec 2022

Segments

2,654 facts

Figures broken down by business line, region, product or another axis the company reports on.

Statement business segments14 members · 2,497 facts

  • Corporate600 · Mar 2011 to Sep 2024
  • Plasma Collection Center478 · Mar 2011 to Mar 2021
  • ADMA Bio Manufacturing383 · Mar 2020 to Sep 2026
  • Plasma Collection Centers355 · Mar 2020 to Sep 2026
  • Adma Biomanufacturing276 · Mar 2016 to Mar 2021
  • Research And Development221 · Mar 2011 to Mar 2017
  • Consolidated88 · Mar 2019 to Mar 2021
  • Corporate26 · Mar 2018 to Sep 2024
  • Admabio manufacturing segment25 · Jun 2020 to Jun 2026
  • Plasma collection centers segment25 · Jun 2020 to Jun 2026
  • Adma biomanufacturing8 · Mar 2018 to Mar 2021
  • Plasma collection center8 · Mar 2018 to Mar 2021
  • Adma biomanufacturing2 · Dec 2019 to Dec 2020
  • Plasma collection center2 · Dec 2019 to Dec 2020

Statement geographical2 members · 89 facts

  • US45 · Mar 2020 to Sep 2026
  • Non Us44 · Mar 2020 to Sep 2026

Product or service4 members · 68 facts

  • ASCENIV23 · Sep 2021 to Dec 2025
  • BIVIGAM15 · Sep 2021 to Dec 2025
  • License And Service15 · Mar 2020 to Dec 2022
  • Product15 · Mar 2020 to Dec 2022

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

  • Earnings-release commentary24 claims from 1 report · Sep 2026
  • Management discussion (MD&A) commentary31 claims from 1 report · Sep 2026
  • Risk-factor changes204 claims from 12 reports · Dec 2013 to Dec 2024
  • Risk factors676 risks from 13 annual reports · 2012 to 2024

Earnings calls

13 calls · Nov 2023 to Nov 2026

Transcripts with management claims and analyst questions, one per fiscal period.

  • FY2026 Q32026-11-04
  • FY2026 Q22026-08-05
  • FY2026 Q12026-05-07
  • FY2025 Q42026-02-25
  • FY2025 Q32025-11-06
  • FY2025 Q22025-08-06
  • FY2025 Q12025-05-07
  • FY2024 Q42025-03-03
  • FY2024 Q32024-11-07
  • FY2024 Q22024-08-08
  • FY2024 Q12024-05-09
  • FY2023 Q42024-02-28
  • FY2023 Q32023-11-08

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of ADMA BIOLOGICS, INC. (ADMA) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Works once FactIQ is connected

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 20, 2026) and refreshed every few hours.

ADMA BIOLOGICS, INC. (ADMA): FY2025 revenue $510M · FactIQ